MDCLF.US MedinCell S.A

Healthcare Biotechnology USA Stocks
34.39 USD
Close of Nov 15, 2026
6.98 34.39
Market cap
USD 1.24B
P/E
-
P/B
320.18x
ROE
-1,025.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Mar 2026.

Is MDCLF.US undervalued?

Graham number

The Graham number of MedinCell S.A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MedinCell S.A fundamental analysis

No fundamental analysis for MedinCell S.A yet.

MedinCell S.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MedinCell S.A

MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, whi…

Full company profile